Zai Lab (9688) Fundamentals 2026 — Revenue Analysis | SniperIQ
Zai Lab (9688) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zai Lab's market cap?
Zai Lab (9688) has a market capitalization of approximately HK
What is Zai Lab's P/E ratio?
Zai Lab's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zai Lab?
Zai Lab runs a net profit margin of -39.3%, a gross margin of 57.9%, and an operating margin of -53.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zai Lab generate?
Zai Lab reported revenue of $461M for fiscal year 2025, with net income of -
Does Zai Lab pay a dividend?
Zai Lab does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Zai Lab financially healthy?
Zai Lab carries a debt-to-equity ratio of 0.35x and a current ratio of 2.40x, with a market beta of 0.76. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zai Lab a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zai Lab (9688) the key facts are: market cap HK
Track Zai Lab's full fundamentals live
Get Zai Lab's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.